The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.
Check out some of NeurologyLive®'s featured content in the carousel below.
The Effect of Aging in Multiple Sclerosis and the Model of Care: Ruth Ann Marrie, MD, PhD, FRCPCDecember 13th 2022
The professor of medicine at the University of Manitoba discussed the need to change how multiple sclerosis is characterized, and how aging contributes to increased disease progression. [WATCH TIME: 4 minutes]
Building the Biomarker Panel in Neurology: Glial Fibrillary Acidic ProteinDecember 9th 2022
As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.
Long-Term Safety of S1P Receptor Modulators in Multiple SclerosisDecember 6th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, examine the safety of sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis.
Brain Health in Multiple SclerosisDecember 6th 2022
An expert panel talks about the preservation of brain health regarding the use of sphingosine 1-phosphate receptor modulators to treat multiple sclerosis.
Expanding the Biomarker Panel in MS: Jens Kuhle, MD, PhDDecember 1st 2022
The senior physician and head of the Multiple Sclerosis Centre at University Hospital Basel spoke about his partnership with Octave and their work assessing and validating biomarkers for use in multiple sclerosis. [WATCH TIME: 4 minutes]
Longitudinal Study to Investigate Health and Lifestyle Behavior Effects on MS: Michelle Chen, PhDNovember 30th 2022
The neuropsychologist at Rutgers University spoke about her recently awarded NIH grant to study the impact of health and lifestyle behaviors in individuals with MS. [WATCH TIME: 3 minutes]
NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MSNovember 30th 2022
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.
Digital Treatment Approach May Help Reduce Healthcare Burden for MS Fatigue: Federica Picariello, PhDNovember 29th 2022
The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]
S1P Receptor Modulator Treatment in Female Patients with MSNovember 29th 2022
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on ponesimod vs teriflunomide for the treatment of female patients with multiple sclerosis who are of childbearing age.
Overview of Sphingosine 1-Phosphate (S1P) Receptor ModulatorsNovember 29th 2022
An expert panel provides an overview of sphingosine-1-phosphate receptor modulators and their use in the treatment of multiple sclerosis.
Using Nonpharmacological Interventions to Promote Healthier Lifestyles in Multiple SclerosisNovember 29th 2022
Michelle Chen, PhD, neuropsychologist at Rutgers University, spoke about her current research grant on the longitudinal impact of health and lifestyle behaviors on cognition with MS.
Changing the Way Multiple Sclerosis Disease Progression is Perceived: Ruth Ann Marrie, MD, PhD, FRCPCNovember 28th 2022
The professor of medicine at the University of Manitoba provided insight on a recently published paper which challenges the way multiple sclerosis is categorized and treated. [WATCH TIME: 5 minutes]
Treating NMOSD Early in the Disease Course: Inebilizumab’s Efficacy in N-MOmentumNovember 26th 2022
Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.
CBT as an Effective Mood Therapy for Patients with MS Experiencing Fatigue: Federica Picariello, PhDNovember 25th 2022
The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the relationship between mood and fatigue in patients with MS. [WATCH TIME: 2 minutes]
Furthering MS Treatment Selection: A Comparative Study of Peginterferon Beta-1a vs Interferon Beta-1aNovember 24th 2022
Peginterferon beta-1a, a pegylated form of interferon designed to maintain biologic effects in the body for longer periods, is being evaluated against CinnaGen’s interferon beta-1a formulation, CinnoVex.
The Relationship Between Epstein-Barr Virus and Multiple SclerosisNovember 23rd 2022
The paradigm-shifting evidence of the link between MS and EBV does not exist in isolation. In fact, the relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades.